⌘K
t
| Date | 21 Mar 2024 |
| Time | 07:00:14 |
| Category | Miscellaneous |
| ID | 6677H |
21 March 2024
Physiomics plc
("Physiomics" or "the Company")
IMC Presentation on Company Website
Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, recently provided a brief update in-line with its interim results via Investor Meet Company and has updated its website with the presentation.
The presentation and Q&A from the meeting are now available at the Company's website:
Enquiries:
Physiomics plc
Dr Jim Millen, Non-Executive Chairman, +44 (0)1235 841575
Dr Peter Sargent, Chief Executive Officer, +44 (0)1235 841575
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics
Physiomics plc combines cutting edge PKPD and QSP modelling and data science techniques, along with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys.
Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design research across discovery, pre-clinical and clinical studies.
Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.